Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 102.69

+5.5%

Dec 19 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	11/12/2015 2:27:57 PM
	of 3202

Haven't seen new data, so don't know if this is a discussion of past stuff. Will poke around. Thanks, as always, to Dr. Ogut and jq1234t...... Ozgur Ogut?@Ogut_Ozgur ABT-494 safety in RA doesn’t look great past 6 mg BID. If dosing limited, then DAS scores may not impress. JQ ?@jq1234t 21h21 hours ago @Ogut_Ozgur $ABBV ABT494 Efficacy plateaued at 12mg BID in BALANCE I compared with 6mg BID in BALANCE II. Seems unlikely to choose 12mg BID. JQ ?@jq1234t 21h21 hours ago @Ogut_Ozgur This is only 12-week study. Would like to see BALANCE II data, if AE profile similar to BALANCE I, $GLPG GLPG0634 better drug. ?@jq1234t 21h21 hours ago @Ogut_Ozgur This reinforces the point $ABBV decision on GLPG0634 was economics based not drug based. Ozgur Ogut ?@Ogut_Ozgur 21h21 hours ago @jq1234t I agree. Interested to see who licenses filgo & deal structure. ABT-494 marginally ahead & bari did better in BEAM than I expected. alex chan ?@tiantianfresh Nov 12 @Ogut_Ozgur It is combined w/ MTX. That might affect the safety data? Ozgur Ogut ?@Ogut_Ozgur Nov 12 @tiantianfresh Well, AEs seem to be dose dependent on ABT-494. And regardless, in RA you need to be able to play nice with MTX.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next